Aura Biosciences, Inc. (AURA) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Aura Biosciences, Inc. (AURA) Earnings Overview
As of June 13, 2026, Aura Biosciences, Inc. (AURA) reported trailing twelve-month net income of -$112M, reflecting -0.6% year-over-year growth. The company earned $-1.67 per diluted share over the past four quarters.
Looking at the long-term picture, AURA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$22M in fiscal 2020.
Aura Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including OCUL (-$290M net income, -513.2% margin), RCKT (-$209M net income), ADVM (-$204M net income, -13092.7% margin), AURA has comparable earnings metrics. Compare AURA vs OCUL →
AURA Earnings vs Peers
Earnings metrics vs comparable public companies
AURA Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$106M | -22.2% | -$113M | $-1.76 | - | - |
| 2024 | -$87M | -13.8% | -$96M | $-1.75 | - | - |
| 2023 | -$76M | -30.0% | -$85M | $-1.93 | - | - |
| 2022 | -$59M | -66.7% | -$60M | $-1.96 | - | - |
| 2021 | -$35M | -58.7% | -$35M | $-1.58 | - | - |
| 2020 | -$22M | +8.2% | -$22M | $-1.03 | - | - |
| 2019 | -$24M | - | -$24M | $-0.01 | - | - |
Download Data
Export AURA earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in AURA back in 2019?
Total return with dividends reinvested · 7+ years of data
Calculate ReturnsHow much would $100/month in AURA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs AURA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationAURA vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowAURA — Frequently Asked Questions
Quick answers to the most common questions about buying AURA stock.
What is AURA earnings per share (EPS)?
AURA trailing twelve-month (TTM) diluted EPS is $-1.67, reflecting -0.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Aura Biosciences, Inc.'s net income?
Aura Biosciences, Inc. (AURA) trailing twelve-month net income is $-112M as of 2025. Earnings declined -0.6% year-over-year.
Is AURA profitable?
AURA is not currently profitable on a TTM basis, reporting a net loss of $-112M. Net margin is N/A. Investors should monitor for a return to profitability.
What is AURA's earnings growth rate?
AURA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are AURA's profit margins?
Aura Biosciences, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -73.5%.
Is AURA growing earnings?
AURA earnings growth is slowing. Current YoY EPS growth of -0.6% trails the 5-year CAGR of N/A. TTM net income is $-112M.
What was AURA's best earnings year?
Aura Biosciences, Inc.'s highest annual net income on record is $-22M, achieved in fiscal year 2020. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were AURA's earnings last quarter?
AURA's most recent reported quarter was Q1 2026. Net income was $-34M with diluted EPS of $-0.50. For a full breakdown of all quarters, see the quarterly earnings table on this page.